Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade.

ABSTRACT:

Background

Immune checkpoint blockade (ICB) has made remarkable achievements, but newly identified armored and cold tumors cannot respond to ICB therapy. The high prevalence of concomitant medications has huge impact on immunotherapeutic responses, but the clinical effects on the therapeutic outcome of armored and cold tumors are still unclear.

Methods

In this research, using large-scale transcriptomics datasets, the expression and potential biological functions of angiotensin II receptor 1 (AGTR1), the target of angiotensin receptor blocker (ARB), were investigated. Next, the roles of ARB in tumor cells and tumor microenvironment cells were defined by a series of in vitro and in vivo assays. In addition, the clinical impacts of ARB on ICB therapy were assessed by multicente

SUBMITTER: Mei J 

PROVIDER: S-EPMC11418576 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature